Comparative retention rates and long-term tolerability of new antiepileptic drugs

Seizure

Volumn 16, Issue 4, 2007, Pages 296-304

  Chung, Steve ^a   Wang, Norman ^a   Hank, Nicole ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Adverse effects; Antiepiletic drugs; Epilepsy treatment; Retention rate; Tolerability

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; TOPIRAMATE; ZONISAMIDE;

ADOLESCENT; ADULT; AGE; AGED; ALLODYNIA; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG RETENTION; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOCAL EPILEPSY; GENDER; GENERALIZED EPILEPSY; HUMAN; HYPONATREMIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROLITHIASIS; PARESTHESIA; PATIENT CODING; PRIORITY JOURNAL; SEDATION; SEIZURE; SENSATION; SIDE EFFECT; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 34247266513     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2007.01.004     Document Type: Article

References (66)

1. From the Centers for Disease Control Prevention. Prevalence of self-reported epilepsy-United States, 1986-1990. JAMA 272 (1994) 1893
2. Prevalence of self-reported epilepsy-United States, 1986-1990. MMWR Morb Mortal Wkly Rep 1994; 43:810-8.
3. Haerer A.F., Anderson D.W., and Schoenberg B.S. Prevalence and clinical features of epilepsy in a biracial United States population. Epilepsia 27 (1986) 66-75
4. Doughty J., Baker G.A., Jacoby A., and Lavaud V. Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav 4 (2003) 710-716
5. Kyngas H. Predictors of good compliance in adolescents with epilepsy. Seizure 10 (2001) 549-553
6. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 342 (2000) 314-319
7. Stephen L.J., and Brodie M.J. Surgery for temporal-lobe epilepsy. N Engl J Med 346 (2002) 292-295
8. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62 (2004) 1252-1260
9. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy: report of the TTA and QSS subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45 (2004) 410-423
10. Sabers A., and Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 60 (2000) 23-33
11. Bromfield E.B. Clinical use of anticonvulsants: a neurologist's perspective. Harv Rev Psychiatry 11 (2003) 257-268
12. Tomson T. Drug selection for the newly diagnosed patient: when is a new generation antiepileptic drug indicated?. J Neurol 251 (2004) 1043-1049
13. Chadwick D., and Wolf P. Meeting the challenge of treating epilepsy. Epileptic Disord 5 Suppl. 1 (2003) S7-S8
14. Mula M., and Trimble M.R. The importance of being seizure free: topiramate and psychopathology in epilepsy. Epilepsy Behav 4 (2003) 430-434
15. Collins R., and Feely M. Practical diagnosis and management of seizures. Practitioner 246 (2002) 188-194
16. Deckers C.L., Knoester P.D., de Haan G.J., Keyser A., Renier W.O., and Hekster Y.A. Selection criteria for the clinical use of the newer antiepileptic drugs. CNS Drugs 17 (2003) 405-421
17. Semah F., Picot M.C., Derambure P., et al. The choice of antiepileptic drugs in newly diagnosed epilepsy: a national French survey. Epileptic Disord 6 (2004) 255-265
18. Lhatoo S.D., Sander J.W., and Shorvon S.D. The dynamics of drug treatment in epilepsy: an observational study in an unselected population based cohort with newly diagnosed epilepsy followed up prospectively over 11-14 years. J Neurol Neurosurg Psychiatry 71 (2001) 632-637
19. Guevara J., Carmona G., Ortega M.P., and Iglesias A.A. Preliminary study on the efficacy and tolerability of newer anticonvulsants in a population of epileptic patients. Med Princ Pract 14 (2005) 31-34
20. Selai C., Bannister D., and Trimble M. Antiepileptic drugs and the regulation of mood and quality of life (QOL): the evidence from epilepsy. Epilepsia 46 Suppl. 4 (2005) 50-57
21. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62 (2004) 1261-1273
22. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs, I: treatment of new-onset epilepsy: report of the TTA and QSS subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45 (2004) 401-409
23. Allison P.D. Survival analysis using the SAS system: a practical guide (1995), SAS Institute Inc., Cary, NC
24. Cox D.R. Regression models and life tables. J. R. Stat. Soc. 74 (1972) 187-220
25. Collett D. Modelling survival data in medical research (1994), Chapman & Hall, London
26. Steyerberg E.W., Eijkemans M.J., Harrell Jr. F.E., and Habbema J.D. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 19 (2000) 1059-1079
27. Brodie M.J., and Kwan P. The star systems: overview and use in determining antiepileptic drug choice. CNS Drugs 15 (2001) 1-12
28. de B., Delvaux V., de Tourchaninoff M., et al. Therapeutic strategies in the choice of antiepileptic drugs. Acta Neurol Belg 102 (2002) 6-10
29. Natsch S., Hekster Y.A., Keyser A., Deckers C.L., Meinardi H., and Renier W.O. Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice. Drug Saf 17 (1997) 228-240
30. Marson A.G., Kadir Z.A., Hutton J.L., and Chadwick D.W. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 38 (1997) 859-880
31. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 3 (2004) 618-621
32. Ferrendelli J.A. Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy. Epilepsia 42 Suppl. 4 (2001) 28-30
33. Chadwick D.W. An overview of the efficacy and tolerability of new antiepileptic drugs. Epilepsia 38 Suppl. 1 (1997) S59-S62
34. Cramer J.A., Fisher R., Ben Menachem E., French J., and Mattson R.H. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 40 (1999) 590-600
35. Lathers C.M., Schraeder P.L., and Claycamp H.G. Clinical pharmacology of topiramate versus lamotrigine versus phenobarbital: comparison of efficacy and side effects using odds ratios. J Clin Pharmacol 43 (2003) 491-503
36. Martin R., Kuzniecky R., Ho S., et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 52 (1999) 321-327
37. Beydoun A., Sachdeo R.C., Kutluay E., McCague K., and D'Souza J. Sustained efficacy and long-term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial epilepsy. Epilepsia 44 (2003) 1160-1165
38. Brodie M.J., Duncan R., Vespignani H., Solyom A., Bitenskyy V., and Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 46 (2005) 31-41
39. Chmielewska B., Kaminski M.L., and Kawka Z. Long-term monotherapy with lamotrigine in newly diagnosed epilepsy in adults. Ann Univ Mariae Curie Sklodowska [Med] 56 (2001) 43-51
40. Dodson W.E., Kamin M., Kraut L., Olson W.H., and Wu S.C. Topiramate titration to response: analysis of individualized therapy study (TRAITS). Ann Pharmacother 37 (2003) 615-620
41. Briggs D.E., and French J.A. Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Saf 3 (2004) 415-424
42. Faught E., Matsuo F.U., Schachter S., Messenheimer J., and Womble G.P. Long-term tolerability of lamotrigine: data from a 6-year continuation study. Epilepsy Behav 5 (2004) 31-36
43. Lhatoo S.D., Wong I.C., and Sander J.W. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 41 (2000) 338-341
44. Bootsma H.P., Coolen F., Aldenkamp A.P., et al. Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 5 (2004) 380-387
45. Collins T.L., Petroff O.A., and Mattson R.H. A comparison of four new antiepileptic medications. Seizure 9 (2000) 291-293
46. Otoul C., Arrigo C., van Rijckevorsel K., and French J.A. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 28 (2005) 72-78
47. Aldenkamp A.P., Baker G., Mulder O.G., et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 41 (2000) 1167-1178
48. Goa K.L., Ross S.R., and Chrisp P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 46 (1993) 152-176
49. Rowan A.J., Ramsay R.E., Collins J.F., et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 64 (2005) 1868-1873
50. Datta P.K., and Crawford P.M. Refractory epilepsy: treatment with new antiepileptic drugs. Seizure 9 (2000) 51-57
51. Lhatoo S.D., Wong I.C., Polizzi G., and Sander J.W. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 41 (2000) 1592-1596
52. Abou-Khalil B., and Lazenby B. Long-term experience with levetiracetam. Epileptic Disord 5 Suppl. 1 (2003) S33-S37
53. Betts T., Yarrow H., Greenhill L., and Barrett M. Clinical experience of marketed Levetiracetam in an epilepsy clinic-a one year follow up study. Seizure 12 (2003) 136-140
54. Deckers C.L., and Renier W.O. Long-term treatment retention with topiramate. Epilepsia 42 (2001) 290-291
55. Krakow K., Walker M., Otoul C., and Sander J.W. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 56 (2001) 1772-1774
56. Knoester P.D., Belitser S.V., Deckers C.L., et al. Patterns of lamotrigine use in daily clinical practice during the first 5 years after introduction in the Netherlands. J Clin Pharm Ther 29 (2004) 131-138
57. Knoester P.D., Belitser S.V., Deckers C.L., et al. Recruitment of a cohort of lamotrigine users through community pharmacists: differences between patients who gave informed consent and those who did not. Pharmacoepidemiol Drug Saf 14 (2005) 107-112
58. Jones M.W. Topiramate-safety and tolerability. Can J Neurol Sci 25 (1998) S13-S15
59. Stephen L.J., Sills G.J., and Brodie M.J. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 41 (2000) 977-980
60. Brodie M.J. Zonisamide clinical trials: European experience. Seizure 13 Suppl. 1 (2004) S66-S70
61. Chadwick D.W., and Marson A.G. Zonisamide for drug-resistant partial epilepsy. Cochrane Database Syst Rev (2000) CD001416
62. Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure 13 Suppl. 1 (2004) S59-S65
63. Kothare S.V., Valencia I., Khurana D.S., Hardison H., Melvin J.J., and Legido A. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 6 (2004) 267-270
64. Peters D.H., Sorkin E.M., and Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 45 (1993) 760-787
65. Rainesalo S., Peltola J., Auvinen A., and Keranen T. Retention rate of oxcarbazepine monotherapy in an unselected population of adult epileptics. Seizure 14 (2005) 72-74
66. Ben Menachem E., and Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 12 (2003) 131-135